Medicare Rx Formulary Proposal Praised By Medco
This article was originally published in The Pink Sheet Daily
Executive Summary
CMS decisions regarding regions and PBM tools are also endorsed by Medco. Major risk for Part D is the aggressive timeline, CEO tells investors.